Simone C. Oostindie

903 total citations · 1 hit paper
14 papers, 599 citations indexed

About

Simone C. Oostindie is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Molecular Biology. According to data from OpenAlex, Simone C. Oostindie has authored 14 papers receiving a total of 599 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Radiology, Nuclear Medicine and Imaging, 7 papers in Immunology and 6 papers in Molecular Biology. Recurrent topics in Simone C. Oostindie's work include Monoclonal and Polyclonal Antibodies Research (12 papers), Glycosylation and Glycoproteins Research (5 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Simone C. Oostindie is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (12 papers), Glycosylation and Glycoproteins Research (5 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Simone C. Oostindie collaborates with scholars based in Netherlands, United States and Denmark. Simone C. Oostindie's co-authors include Janine Schuurman, Paul W.H.I. Parren, Greg A. Lazar, Frank J. Beurskens, Sandra Verploegen, Patrick Engelberts, Kristin Strumane, Rob N. de Jong, Esther C.W. Breij and Muriel D. van Kampen and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Nature Biotechnology.

In The Last Decade

Simone C. Oostindie

14 papers receiving 581 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Avidity in antibody effector functions and biotherapeutic drug design

2022 141 citations Simone C. Oostindie, Greg A. Lazar et al. Nature Reviews Drug Discovery profile →

Peers

Simone C. Oostindie

RNMI

IMMUN

ONCOL

GENET

Irene Ni United States

Sean C. Yoder United States

Geir Åge Løset Norway

Sofia Kossida France

Rodrigo Vazquez-Lombardi Australia

Bernd Hubner Germany

Alexander V. Taranin Russia

Johan Lantto United States

Paul R. Hinton United States

Anneke W. Reurs Netherlands

Irene Ni United States

Simone C. Oostindie

379 ×1.0

RNMI

356 ×1.3

IMMUN

347 ×1.6

166 ×0.9

ONCOL

39 ×0.6

GENET

Citations per year, relative to Simone C. Oostindie Simone C. Oostindie (= 1×) peers Irene Ni

Countries citing papers authored by Simone C. Oostindie

Since Specialization

Citations

This map shows the geographic impact of Simone C. Oostindie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simone C. Oostindie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simone C. Oostindie more than expected).

Fields of papers citing papers by Simone C. Oostindie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simone C. Oostindie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simone C. Oostindie. The network helps show where Simone C. Oostindie may publish in the future.

Co-authorship network of co-authors of Simone C. Oostindie

This figure shows the co-authorship network connecting the top 25 collaborators of Simone C. Oostindie. A scholar is included among the top collaborators of Simone C. Oostindie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simone C. Oostindie. Simone C. Oostindie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Oostindie, Simone C., Gijs G. Zom, Michael J. Wester, et al.. (2022). Logic-gated antibody pairs that selectively act on cells co-expressing two antigens. Nature Biotechnology. 40(10). 1509–1519. 31 indexed citations

Oostindie, Simone C., Greg A. Lazar, Janine Schuurman, & Paul W.H.I. Parren. (2022). Avidity in antibody effector functions and biotherapeutic drug design. Nature Reviews Drug Discovery. 21(10). 715–735. 141 indexed citations breakdown →

Oostindie, Simone C., Mir Farshid Alemdehy, Maarten L. Janmaat, et al.. (2022). Duobody-CD3xCD30 Demonstrates Potent Anti-Tumor Activity in Preclinical Models of CD30+ Hematologic Malignancies. Blood. 140(Supplement 1). 3153–3154. 6 indexed citations

Kan, Andrey, Simone C. Oostindie, Simon J. Dovedi, et al.. (2021). Cyton2: A Model of Immune Cell Population Dynamics That Includes Familial Instructional Inheritance. SHILAP Revista de lepidopterología. 1. 723337–723337. 7 indexed citations

Engelberts, Patrick, Ida H. Hiemstra, Danita H. Schuurhuis, et al.. (2020). DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 52. 102625–102625. 102 indexed citations

Oostindie, Simone C., Hilma J. van der Horst, Laurens P. Kil, et al.. (2020). DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies. Blood Cancer Journal. 10(3). 30–30. 49 indexed citations

Horst, Hilma J. van der, Simone C. Oostindie, Saskia A.G.M. Cillessen, et al.. (2020). Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies. HemaSphere. 5(1). e504–e504. 5 indexed citations

Oostindie, Simone C., Hilma J. van der Horst, Margaret A. Lindorfer, et al.. (2019). CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering. Haematologica. 104(9). 1841–1852. 40 indexed citations

Lubbers, Rosalie, Simone C. Oostindie, Paul W.H.I. Parren, et al.. (2019). Carbamylation reduces the capacity of IgG for hexamerization and complement activation. Clinical & Experimental Immunology. 200(1). 1–11. 14 indexed citations

10.

Horst, Hilma J. van der, Simone C. Oostindie, Saskia A.G.M. Cillessen, et al.. (2018). Targeting CD37 in B-Cell Malignancies Using the Novel Therapeutic Duohexabody-CD37 Results in Efficient Killing of Tumor B-Cells Ex Vivo Via Complement-Dependent Cytotoxicity, Even in Relapsed and/or Refractory Patient Samples. Blood. 132(Supplement 1). 4179–4179. 1 indexed citations

11.

Taylor, Ronald P., Margaret A. Lindorfer, Simone C. Oostindie, et al.. (2018). Hexamerization-enhanced CD37 and CD20 antibodies synergize in CDC to kill patient-derived CLL cells with unprecedented potency. Molecular Immunology. 102. 218–218. 1 indexed citations

12.

Cook, Erika M., Margaret A. Lindorfer, Simone C. Oostindie, et al.. (2016). Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions. The Journal of Immunology. 197(5). 1762–1775. 48 indexed citations

13.

Jong, Rob N. de, Frank J. Beurskens, Sandra Verploegen, et al.. (2016). A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface. PLoS Biology. 14(1). e1002344–e1002344. 153 indexed citations

14.

Taylor, Ronald P., Margaret A. Lindorfer, Erika M. Cook, et al.. (2016). Antibodies that efficiently form hexamers upon antigen binding can induce complement-dependent cytotoxicity under complement-limiting conditions. Immunobiology. 221(10). 1132–1132. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact